Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary

Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.

Original reporting
Published Sep 10, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary — source image
Decision brief

The 30-second read

$ALZNBearishLow
01

Why it matters

The earnings release confirms continued R&D spend with no commercial revenue, likely pressuring the stock.

02

Market read

Micro‑cap biotech earnings with no revenue; relevant for traders tracking early‑stage biotech risk.

03

What to watch

Partnerships with MGH/Harvard and Tesla Dynamic Coils could de‑risk future trials.

Relevance 7/10Novelty 8/10Timing: post‑market release

Background

Alzamend Neuro is a clinical‑stage neuro‑technology company developing AL001 and ALZN002.

Company-level read

Ticker impact

$ALZNBearishMedium confidence
Context

Alzamend Neuro filed its Q1 2027 10‑Q showing a $3.03M net loss and no product revenue.

Expected impact

Potential short‑term downside pressure as investors digest the loss.

Evidence & confidence

Micro‑cap biotech earnings often move sharply on cash‑flow results; no revenue and a larger loss suggest heightened risk.

Market effects

Highlights ongoing funding challenges for early‑stage neuro‑tech firms.

Limited to US biotech niche; no broader market effect.

Minimal, as the company is a micro‑cap with niche focus.

Counterpoint

If the Phase II data prove compelling, the loss may be viewed as a temporary investment in pipeline value.

Key entities

  • Alzamend Neuro, Inc.

    Clinical‑stage neuro‑technology firm.

Related articles

$ALZNMed

Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

$ALZNMed

In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase

$ALZNMedAI 8/10

Alzamend Neuro, Inc. (ALZN): Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation :

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqin

$AZIOMedAI 8/10

Azio AI 3Q 2026: Revenue $1.87M, EPS ($0.34) — 10-Q Summary

Azio AI reported 3Q 2026 revenue of $1.87M, up 3.3% YoY, and a net loss of $0.34 per share, narrowed 9.7%. Sales were driven by medical supplies to a related party, while higher G&A costs, including a $860,428 stock-based compensation adjustment, offset gains from debt settlement. AI infrastructure segment generated no revenue.